Becton Dickinson downgraded by Citigroup with a new price target
$BDX
Medical/Dental Instruments
Health Care
Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2025 | $185.00 | Buy → Neutral | Citigroup |
| 5/2/2025 | $185.00 | Overweight → Neutral | Piper Sandler |
| 5/2/2025 | $192.00 | Buy → Neutral | Goldman |
| 5/2/2025 | Outperform → Mkt Perform | Raymond James | |
| 5/1/2025 | Overweight → Equal Weight | Wells Fargo | |
| 5/1/2025 | $190.00 | Buy → Neutral | BofA Securities |
| 5/1/2025 | Outperform → Mkt Perform | William Blair | |
| 10/1/2024 | $255.00 → $275.00 | Neutral → Buy | Citigroup |
Citigroup downgraded Becton Dickinson from Buy to Neutral and set a new price target of $185.00
Piper Sandler downgraded Becton Dickinson from Overweight to Neutral and set a new price target of $185.00
Goldman downgraded Becton Dickinson from Buy to Neutral and set a new price target of $192.00
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)